{
    "title": "Trial fails of ruxolitinib in COVID-19 complications- Novartis",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-9050443/Trial-fails-ruxolitinib-COVID-19-complications-Novartis.html",
    "date": "2020-12-14",
    "keywords": [
        "trial",
        "ruxolitinib",
        "novartis",
        "covid19",
        "ruxcovid",
        "jak",
        "development",
        "latestage",
        "top",
        "therapy",
        "reduction",
        "death",
        "respiratory",
        "failure",
        "ventilation",
        "admission",
        "care",
        "unit",
        "benefit",
        "mortality",
        "rate",
        "day",
        "time",
        "recovery",
        "drugmaker",
        "monday",
        "setback",
        "coronavirus",
        "inhibitor",
        "tyrosine",
        "incyte",
        "corp",
        "commercialisation",
        "trade",
        "name",
        "jakavi",
        "europe",
        "adult",
        "polycythemia",
        "vera",
        "pv",
        "myelofibrosis",
        "mf",
        "community",
        "role",
        "inhibition",
        "tsai",
        "head",
        "drug",
        "officer",
        "study",
        "jakafi",
        "reporting",
        "michael",
        "thomas",
        "seythal",
        "louise"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}